News Briefing channel feed

In 1-2 punch, Mol­e­c­u­lar Tem­plates cuts first-gen can­di­date and los­es a Big Phar­ma part­ner; Charles Riv­er teams up with Va­lence to pro­vide AI dis­cov­ery plat­form

5 years ago

Watch out, Bris­tol My­ers — J&J is right be­hind you; Blake By­ers leaps out from GV to do his own thing

5 years ago

Unit­ed Ther­a­peu­tics bags a new OK on Ty­va­so, with block­buster ex­pec­ta­tions; Gilead goes back to Ab­Celler­a's well with a set of fresh tar­gets

5 years ago

Bausch Health sells off Amoun for $740M; Achilles de­buts on Nas­daq with $175.5M IPO

5 years ago

For­ma sees da­ta 'sup­port­ing' sick­le cell ther­a­py dos­ing lev­els; Lian­Bio teams with Tar­sus for eye ir­ri­ta­tion in Chi­na

5 years ago

Tem­pest Ther­a­peu­tics jumps on­to Nas­daq in merg­er with strug­gling Mil­len­do Ther­a­peu­tics; Bio­haven hits $100M mile­stone as it gears up for a late-stage study in mi­graine pa­tients

5 years ago

JSR Life Sci­ences spawns new ven­ture fund; IL-2 biotech com­pletes merg­er with triv­ia com­pa­ny sub­sidiary

5 years ago

SEC opens in­quiry in­to Wall Street's SPAC ma­nia — re­port; A Chi­na-based gene ther­a­py play­er now has $80M more in the bank

5 years ago

My­ovant adds re­l­u­golix da­ta in uter­ine fi­broids ahead of June PDU­FA; Mubadala teams up with UK for $1B+ fund

5 years ago

Jeff Aron­in's Emalex rais­es $35M Se­ries C; British pro­tein degra­da­tion biotech emerges from stealth

5 years ago

Three biotechs set terms in a hunt for $475M-plus; Leap Ther­a­peu­tics earns a tri­al win across DKK1 high ex­press­ing tu­mors

5 years ago

FDA ac­cepts Bris­tol My­er­s' pitch for for­mer MyoKar­dia drug; Clo­vis' Rubra­ca aces ad­vanced ovar­i­an can­cer study

5 years ago

Gilead and No­vo Nordisk ex­pand NASH deal with new study; Pfiz­er out-li­cens­es AD­Cs to a biotech start­up

5 years ago

New Pur­due bank­rupt­cy plan round­ly crit­i­cized as Sack­lers of­fer $4B+; Sana seals pact with Fu­ji­film for iP­SC-de­rived ther­a­pies

5 years ago

Roche builds long-term case for Evrys­di with 2-year SMA da­ta; Ex­e­Vir nets $50M Se­ries A for lla­ma-de­rived Covid an­ti­body

5 years ago

Galec­to shelves high dose of IPF drug af­ter SAE im­bal­ance; Long­time Aveo part­ner hands back HER3 an­ti­body

5 years ago

Aveo teams with Bris­tol My­ers af­ter sur­prise FDA ap­proval; Cal­ciMed­ica lines up $21M raise to ad­vance Covid-19 can­di­date

5 years ago

Prometheus up­sizes IPO by 33% ahead of pric­ing; Hu­mani­gen se­cures loan of up to $80M to de­vel­op lenzilum­ab

5 years ago

Gri­fols snags the rest of Gi­ga­Gen in $80M ac­qui­si­tion; Ver­tex moves cut­ting-edge di­a­betes treat­ment in­to the clin­ic

5 years ago

Mer­ck inks Keytru­da deal with Sur­face On­col­o­gy; Rock­et Phar­ma­ceu­ti­cals gets ex­pe­dit­ed re­view of gene ther­a­py for rare pe­di­atric dis­ease 

5 years ago

Mount Sinai leas­ing of­fice space for out­pa­tient clin­ics, biotech re­search; Zol­gens­ma OK to be sold in UK, NICE says

5 years ago

Seagen warns in­vestors against TRC Cap­i­tal’s lat­est 'mi­ni-ten­der of­fer'; BeiGene goes af­ter a new in­di­ca­tion for top PD-1 play­er

5 years ago

Gala­pa­gos posts a safe­ty win for fil­go­tinib, but is it too lit­tle, too late?; Bio-Techne inks $320M mol­e­c­u­lar di­ag­nos­tics buy­out

5 years ago

Presage teams with Mer­ck on its Phase 0 test­ing; Kem­Pharm AD­HD drug wins ap­proval in chil­dren aged 6 and up

5 years ago
First page Previous page 32333435363738 Next page Last page
A service from the Financial Times